Drug Profile
Research programme: anti-CMV monoclonal antibodies - AVANIR
Alternative Names: Anti-CMV monoclonal antibodies research programme - AVANIRLatest Information Update: 17 Mar 2017
Price :
$50
*
At a glance
- Originator Avanir Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 14 Mar 2006 No development reported - Preclinical for Cytomegalovirus infections treatment in USA (unspecified route)
- 08 May 2003 Preclinical trials in Cytomegalovirus infections in USA (unspecified route)